SCHEMBL16385294

SCHEMBL16385294

CCc1cccc(-c2ccc(O)c(C)c2)n1

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HSD17B1 P14061 7/20 0.51
HSD17B2 P37059 7/20 0.51
HSD17B14 Q9BPX1 2/20 0.51
ESR2 Q92731 8/20 0.45
CDC7 O00311 1/20 0.44
PIM1 P11309 1/20 0.44
CSNK2A2 P19784 1/20 0.44
CLK1 P49759 1/20 0.44
GSK3B P49841 1/20 0.44
CSNK2B P67870 1/20 0.44
CSNK2A1 P68400 1/20 0.44
CSNK2A3 Q8NEV1 1/20 0.44
ESR1 P03372 8/20 0.44
AR P10275 1/20 0.44
TLR8 Q9NR97 1/20 0.42
IRAK4 Q9NWZ3 2/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C19 P33261 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13273049 0.81 MEN1 (0.43) HSD17B1HSD17B2HSD17B14PIM1GSK3B
SCHEMBL16384971 0.80 HSD17B1 (0.56) HSD17B1HSD17B2HSD17B14ESR2CDC7
SCHEMBL16385241 0.80 HSD17B1 (0.49) HSD17B1HSD17B2ESR2ESR1AR
SCHEMBL16385399 0.79 KDM4E (0.49)
SCHEMBL16385310 0.78 ALDH1A1 (0.41) HSD17B1HSD17B2HSD17B14ESR2ESR1
SCHEMBL16385301 0.78 ESR2 (0.56) HSD17B1HSD17B2HSD17B14ESR2CDC7
SCHEMBL28888400 0.77 CTSS (0.49) TLR8
SCHEMBL28396757 0.76 SREBF2 (0.44) IRAK4
SCHEMBL13831046 0.76 CYP1A2 (0.46) HSD17B1HSD17B2ESR2ESR1AR
SCHEMBL16385298 0.74 HSD17B1 (0.53) HSD17B1HSD17B2HSD17B14ESR2CDC7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3020715-B1 TETRAZOLINONE COMPOUND AND USE THEREOF SUMITOMO CHEMICAL CO (JP) 2021-06-16 EP disclosed
EP-3020715-B1 TETRAZOLINONE COMPOUND AND USE THEREOF SUMITOMO CHEMICAL CO (JP) 2021-06-16 EP disclosed
CN-105324373-B Tetrazolinone compound and use thereof 住友化学株式会社 2018-02-16 CN disclosed
US-9888688-B2 Tetrazolinone compounds and applications thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2018-02-13 US disclosed
US-9888688-B2 Tetrazolinone compounds and applications thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2018-02-13 US disclosed
US-9888688-B2 Tetrazolinone compounds and applications thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2018-02-13 US disclosed
US-20160150787-A1 TETRAZOLINONE COMPOUNDS AND APPLICATIONS THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2016-06-02 US disclosed
US-20160150787-A1 TETRAZOLINONE COMPOUNDS AND APPLICATIONS THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2016-06-02 US disclosed
US-20160150787-A1 TETRAZOLINONE COMPOUNDS AND APPLICATIONS THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2016-06-02 US disclosed
EP-3020715-A1 TETRAZOLINONE COMPOUND AND USE THEREOF Sumitomo Chemical Company Limited (JP) 2016-05-18 EP disclosed
WO-2015005499-A1 TETRAZOLINONE COMPOUND AND USE THEREOF 住友化学株式会社 (JP) 2015-01-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160150787-A1 TETRAZOLINONE COMPOUNDS AND APPLICATIONS THEREOF SOD1, UQCRB, MT-CO1 HSD17B1 1419/4885HSD17B2 2000/4885HSD17B14 3208/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.